Filing Details
- Accession Number:
- 0001209191-24-002392
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-01-29 20:01:22
- Reporting Period:
- 2024-01-25
- Accepted Time:
- 2024-01-29 20:01:22
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1672619 | Enliven Therapeutics Inc. | ELVN | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1967168 | Samuel Kintz | C/O Enliven Therapeutics, Inc. 6200 Lookout Road Boulder CO 80301 | President And Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-01-25 | 12,000 | $1.12 | 12,000 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-01-25 | 2,542 | $14.94 | 9,458 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2024-01-25 | 9,458 | $15.89 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2024-01-25 | 12,000 | $0.00 | 12,000 | $1.12 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 284,550 | 2030-06-15 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 1,087,525 | Indirect | See footnote |
| Common Stock | 88,531 | Indirect | See footnote |
| Common Stock | 88,531 | Indirect | See footnote |
Footnotes
- The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023.
- This transaction was executed in multiple trades at prices ranging from $14.35 to $15.33. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- This transaction was executed in multiple trades at prices ranging from $15.35 to $16.31. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee.
- The shares are held of record by an irrevocable trust dated October 26, 2021 for the benefit of the Reporting Person's elder son and for which the Reporting Person serves as an investment advisor.
- The shares are held of record by an irrevocable trust dated October 26, 2021 for the benefit of the Reporting Person's younger son and for which the Reporting Person serves as an investment advisor.
- The option, originally for 344,550 shares, is subject to an early exercise provision and is immediately exercisable. Shares subject to the option vest in 48 equal monthly installments beginning on May 3, 2020.
Billionaire Hedge Funds
